TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20810998

Group type: EXPERIMENTAL
Intervention: Donepezil (maximum 10 mg per day)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 19075497

Group type: EXPERIMENTAL
Intervention: Folic acid at 1 mg/day
Number of subjects: 202

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 202
Study: 16162698

Group type: EXPERIMENTAL
Intervention: Salmeterol, 50 microg
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Formoterol, 12 microg
Number of subjects: 39
Study: 12952833

Group type: EXPERIMENTAL
Intervention: Low-dose paclitaxel (1.28 microg/mm2)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: High-dose paclitaxel (3.10 microg/mm2)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Positive remodeling lesions
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Intermediate remodeling lesions
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Negative remodeling lesions
Number of subjects: 39
Study: 10232867

Group type: EXPERIMENTAL
Intervention: Diary cards used alone
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Diary cards with physician assessment
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Visual analogue scale
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Likert scales
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Daily averages of symptoms
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Weekly averages of symptoms
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: 2-week intervals during treatment
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Quality of life questionnaires
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Psychometric test
Number of subjects: 67
Study: 8681000

Group type: EXPERIMENTAL
Intervention: Interpersonal Counseling (IPC)
Number of subjects: 76
Study: 1925430

Group type: EXPERIMENTAL
Intervention: Individually planned energy-restricted diet of 1000-1500 kcal per day, weekly discussions, and various leaflets on diet modification and increase of physical activity
Number of subjects: 49

Group type: COMPARATOR
Intervention: Control group (no specific intervention details provided)
Number of subjects: 49
Study: 6660028

Group type: EXPERIMENTAL
Intervention: Activated charcoal (20 g X 4/day)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Haemodialysis (3 treatments of 5 hours each)
Number of subjects: 3

Group type: COMPARATOR
Intervention: Activated charcoal
Number of subjects: 3
Study: 30924895

Group type: EXPERIMENTAL
Intervention: PACT (Protect and Connect) intervention
Number of subjects: 230

Group type: COMPARATOR
Intervention: HIV CTR control
Number of subjects: 230
Study: 28957643

Group type: EXPERIMENTAL
Intervention: Patients with a ratio below LLN
Number of subjects: 17072

Group type: COMPARATOR
Intervention: 5 μg tiotropium Respimat
Number of subjects: 17072

Group type: COMPARATOR
Intervention: 18 μg HandiHaler
Number of subjects: 17072
Study: 25810425

Group type: EXPERIMENTAL
Intervention: Conventional exercise training with inspiratory muscle training (8 weeks)
Number of subjects: 54
Study: 25300273

Group type: EXPERIMENTAL
Intervention: LPCaC14:0 at age 6 months
Number of subjects: 726

Group type: EXPERIMENTAL
Intervention: LPCaC14:0
Number of subjects: 726
Study: 22472154

Group type: EXPERIMENTAL
Intervention: morphine (0.05 mg/kg) IV during gallbladder extraction and (0.15 mg/kg) for 40 min postoperatively
Number of subjects: 40

Group type: COMPARATOR
Intervention: ketorolac (0.2 mg/kg) IV during gallbladder extraction and (0.7 mg/kg) for 40 min postoperatively
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: morphine
Number of subjects: 40
Study: 20353029

Group type: EXPERIMENTAL
Intervention: Modified Huanglian Wendan Decoction (HWD) 200 mL, twice a day
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Modified Huanglian Wendan Decoction (HWD)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Aniracetam 0.2 g (0.1 g for patients over 70), three times a day
Number of subjects: 64

Group type: COMPARATOR
Intervention: Modified Huanglian Wendan Decoction (HWD) and Aniracetam
Number of subjects: 64
Study: 17307300

Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI) adherence
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: Adherence to MI
Number of subjects: 163
Study: 16107896

Group type: EXPERIMENTAL
Intervention: AML-82 protocol
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: AML-87 protocol (based on BFM-87) with prophylactic cranial irradiation in high-risk patients
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: AML-92/94 protocol (modified BFM-93) without maintenance therapy and prophylactic cranial irradiation
Number of subjects: 209
Study: 11810342

Group type: EXPERIMENTAL
Intervention: Music therapy (8 group sessions)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Waiting group (control)
Number of subjects: 34
Study: 9231815

Group type: EXPERIMENTAL
Intervention: ET-1 infusion (0.5 ng/kg per minute for 60 minutes, then 1.0 ng/kg per minute for 60 minutes, and finally 2.0 ng/kg per minute for 60 minutes)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Enalapril (20 mg BID)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Nifedipine (60 mg OD)
Number of subjects: 9
Study: 8186511

Group type: EXPERIMENTAL
Intervention: L-phenylalanine (L-Phe) plus UVA irradiation
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: Increased L-phenylalanine dose
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: Optimal L-phenylalanine dose
Number of subjects: 181
Study: 3578096

Group type: EXPERIMENTAL
Intervention: White bread made from gluten-free flour
Number of subjects: 0

Group type: COMPARATOR
Intervention: White bread made from regular flour
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Addition of gluten to gluten-free bread mix
Number of subjects: 0
Study: 31066792

Group type: EXPERIMENTAL
Intervention: Radiofrequency thermoablation
Number of subjects: 49

Group type: COMPARATOR
Intervention: Complete saphenous vein stripping
Number of subjects: 49
Study: 28728282

Group type: EXPERIMENTAL
Intervention: Tear film lipid layer thickness (LLT) measurement
Number of subjects: 473

Group type: EXPERIMENTAL
Intervention: Ocular Surface Disease Index (OSDI) questionnaire
Number of subjects: 473

Group type: EXPERIMENTAL
Intervention: Statistical analysis of LLT by age groups
Number of subjects: 473

Group type: COMPARATOR
Intervention: Comparison of LLT by gender
Number of subjects: 473

Group type: COMPARATOR
Intervention: Correlation analysis with TBUT, SchirmerⅠtest, meibomian gland loss rate
Number of subjects: 473
Study: 25423323

Group type: EXPERIMENTAL
Intervention: Bilateral salpingo-oophorectomy (BSO) without subsequent hormone therapy (HT)
Number of subjects: 8879

Group type: COMPARATOR
Intervention: Retaining ovaries
Number of subjects: 8879
Study: 22722891

Group type: EXPERIMENTAL
Intervention: Almond diet (56 g/day, replacing 20% of total daily calorie intake)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control diet (NCEP step II diet)
Number of subjects: 20
Study: 21979855

Group type: EXPERIMENTAL
Intervention: Silver-containing soft silicone foam dressing (Mepilex Ag)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Silver sulfadiazine cream
Number of subjects: 101
Study: 19860915

Group type: EXPERIMENTAL
Intervention: High-dose N-acetylcysteine (NAC)
Number of subjects: 155

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 155
Study: 17085655

Group type: EXPERIMENTAL
Intervention: Tamoxifen (2 years)
Number of subjects: 400

Group type: COMPARATOR
Intervention: Untreated patients
Number of subjects: 400
Study: 15301636

Group type: EXPERIMENTAL
Intervention: Coping self-efficacy measured using a modified Situational Confidence Questionnaire (SCQ)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Early abstinence
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Early confidence
Number of subjects: 126
Study: 11154711

Group type: EXPERIMENTAL
Intervention: Maternal verbal abuse during childhood
Number of subjects: 793

Group type: COMPARATOR
Intervention: No maternal verbal abuse
Number of subjects: 793
Study: 9086464

Group type: EXPERIMENTAL
Intervention: Botulinum neurotoxin serotype C
Number of subjects: 3

Group type: COMPARATOR
Intervention: Botulinum neurotoxin serotype A
Number of subjects: 3
Study: 7959144

Group type: EXPERIMENTAL
Intervention: Clindamycin vaginal cream (2%)
Number of subjects: 184

Group type: COMPARATOR
Intervention: Oral metronidazole
Number of subjects: 184
Study: 2888637

Group type: EXPERIMENTAL
Intervention: Diphenhydramine (DPH) 50 mg
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Temazepam 15 mg
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 28759496

Group type: EXPERIMENTAL
Intervention: BVM with NC at 0 lpm
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: BVM with NC at 5 lpm
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: BVM with NC at 10 lpm
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: BVM with NC at 15 lpm
Number of subjects: 0

Group type: COMPARATOR
Intervention: BVM-only
Number of subjects: 0
Study: 27686943

Group type: EXPERIMENTAL
Intervention: Temozolomide chemotherapy (75 mg/m2 daily, for 21 of 28 days for 12 cycles)
Number of subjects: 477

Group type: COMPARATOR
Intervention: Radiotherapy (50·4 Gy in 28 fractions of 1·8 Gy for 5 days per week up to 6·5 weeks)
Number of subjects: 477

Group type: EXPERIMENTAL
Intervention: Temozolomide chemotherapy
Number of subjects: 477

Group type: COMPARATOR
Intervention: Radiotherapy
Number of subjects: 477
Study: 25210752

Group type: EXPERIMENTAL
Intervention: Standardized exercise test
Number of subjects: 39
Study: 23325917

Group type: EXPERIMENTAL
Intervention: High-carbohydrate (HC) meals
Number of subjects: 52

Group type: COMPARATOR
Intervention: High-protein (HP) meals
Number of subjects: 52
Study: 22136578

Group type: EXPERIMENTAL
Intervention: Group-based intensive program
Number of subjects: 534

Group type: EXPERIMENTAL
Intervention: Pedometer-based walking program
Number of subjects: 534

Group type: COMPARATOR
Intervention: Active control group
Number of subjects: 534
Study: 19929975

Group type: EXPERIMENTAL
Intervention: AZ-ER (single oral 2-g dose)
Number of subjects: 598

Group type: COMPARATOR
Intervention: AZ-IR (3 days, 500 mg once daily)
Number of subjects: 598
Study: 16387893

Group type: EXPERIMENTAL
Intervention: 2 g i.v. carnitine
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 15508346

Group type: EXPERIMENTAL
Intervention: Milrinone irrigation
Number of subjects: 12

Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 12
Study: 12243707

Group type: EXPERIMENTAL
Intervention: Oral ketoconazole 600 mg/day for adults and 10 mg/kg per day for children for 30 days
Number of subjects: 96

Group type: COMPARATOR
Intervention: Intra-lesional meglumine antimoniate (Glucantime) with 6-8 biweekly injections
Number of subjects: 96
Study: 7900613

Group type: EXPERIMENTAL
Intervention: Aspirin use (even infrequent)
Number of subjects: 90

Group type: COMPARATOR
Intervention: No aspirin use
Number of subjects: 90
Study: 2670331

Group type: EXPERIMENTAL
Intervention: Intravenous glucose (50%), insulin (80 units/I), and potassium (100 meq/l) (GIK) infused at a rate of 1 ml/kg/hr for up to 48 hours
Number of subjects: 22

Group type: COMPARATOR
Intervention: Glucose (5%) and NaCl (0.225%) infused at the same rate (control)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: GIK
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control
Number of subjects: 22
Study: 796942

Group type: EXPERIMENTAL
Intervention: Ketoprofen
Number of subjects: 0

Group type: COMPARATOR
Intervention: Indomethacin
Number of subjects: 0
Study: 31189509

Group type: EXPERIMENTAL
Intervention: Dulaglutide (1.5 mg weekly subcutaneous injection)
Number of subjects: 9901

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9901

Group type: EXPERIMENTAL
Intervention: Dulaglutide
Number of subjects: 9901
Study: 28471553

Group type: EXPERIMENTAL
Intervention: Parietal infiltration with ropivacaine
Number of subjects: 0
Study: 25681529

Group type: EXPERIMENTAL
Intervention: CDP-choline 500mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: CDP-choline 1000mg
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 25096607

Group type: EXPERIMENTAL
Intervention: 12-week progressive resistance training (2 times/week)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Relaxation control (RC, 2 times/week)
Number of subjects: 160
Study: 21946980

Group type: EXPERIMENTAL
Intervention: Mobile bearing total knee prosthesis
Number of subjects: 92

Group type: COMPARATOR
Intervention: Fixed bearing total knee prosthesis
Number of subjects: 92
Study: 21165880

Group type: EXPERIMENTAL
Intervention: Experimental room (semicircular table, equal access to computer screen)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Experimental room
Number of subjects: 65

Group type: COMPARATOR
Intervention: Standard room
Number of subjects: 65
Study: 17950093

Group type: EXPERIMENTAL
Intervention: Pulsatile intravenous insulin infusion (3 one-hour courses per week)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Subcutaneous insulin (3-4 injections per day)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Pulsatile intravenous insulin infusion
Number of subjects: 18

Group type: COMPARATOR
Intervention: Subcutaneous insulin
Number of subjects: 18
Study: 16342005

Group type: EXPERIMENTAL
Intervention: Lithium administration
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo administration
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Lithium serum levels > 0.5 meq/l
Number of subjects: 12
Study: 11928799

Group type: EXPERIMENTAL
Intervention: irinotecan
Number of subjects: 0

Group type: COMPARATOR
Intervention: 5‐fluorouracil (5‐FU)‐based chemotherapy
Number of subjects: 0
Study: 9456255

Group type: EXPERIMENTAL
Intervention: Oral nutritional supplement with arginine and omega-3 fatty acids
Number of subjects: 64

Group type: COMPARATOR
Intervention: Oral nutritional supplement without arginine and omega-3 fatty acids (Control)
Number of subjects: 64
Study: 8943592

Group type: EXPERIMENTAL
Intervention: 90 degrees anticlockwise rotation
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 180 degrees anticlockwise rotation then back to 90 degrees anticlockwise (overcorrected rotation)
Number of subjects: 90

Group type: COMPARATOR
Intervention: No rotation (neutral position)
Number of subjects: 90
Study: 1760685

Group type: EXPERIMENTAL
Intervention: Sutured anastomoses
Number of subjects: 294

Group type: COMPARATOR
Intervention: Stapled anastomoses
Number of subjects: 294
Study: 6282524

Group type: EXPERIMENTAL
Intervention: Potassium canrenoate
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Furosemide
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Potassium canrenoate with furosemide and digoxin
Number of subjects: 6

Group type: COMPARATOR
Intervention: Digoxin
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 30713413

Group type: EXPERIMENTAL
Intervention: Not applicable (this study focuses on exclusion criteria rather than a specific intervention)
Number of subjects: 1206

Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 1206
Study: 28391912

Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg/day for 4 weeks then 20 mg/day for 16 weeks
Number of subjects: 98

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 98
Study: 25512403

Group type: EXPERIMENTAL
Intervention: Faldaprevir with TID deleobuvir for 16 weeks
Number of subjects: 362

Group type: EXPERIMENTAL
Intervention: Faldaprevir with TID deleobuvir for 28 weeks
Number of subjects: 362

Group type: EXPERIMENTAL
Intervention: Faldaprevir with TID deleobuvir for 40 weeks
Number of subjects: 362

Group type: EXPERIMENTAL
Intervention: Faldaprevir with BID deleobuvir for 28 weeks
Number of subjects: 362

Group type: EXPERIMENTAL
Intervention: Faldaprevir with TID deleobuvir and no ribavirin for 28 weeks
Number of subjects: 362
Study: 25250279

Group type: EXPERIMENTAL
Intervention: Percutaneous technique
Number of subjects: 35

Group type: COMPARATOR
Intervention: Open surgical technique
Number of subjects: 35
Study: 21719555

Group type: EXPERIMENTAL
Intervention: Darbepoetin (60 μg/injection)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (saline injections)
Number of subjects: 20
Study: 19302119

Group type: EXPERIMENTAL
Intervention: 25% Caloric Restriction (CR)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: 12.5% Caloric Restriction plus Exercise (CR + EX)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Low-Calorie Diet (LCD; 3724 kJ day(‐1) (890 kcal day(‐1)))
Number of subjects: 48

Group type: COMPARATOR
Intervention: Healthy Diet (Control)
Number of subjects: 48
Study: 17711731

Group type: EXPERIMENTAL
Intervention: Group I: Propofol 2 microg/ml and Rimifentanil 2 ng/ml with fluid expansion of Hetastarch 5 ml/kg
Number of subjects: 90

Group type: COMPARATOR
Intervention: Group II (Control): Propofol 4 microg/ml and Rimifentanil 4 ng/ml with fluid expansion of Hetastarch 10 ml/kg
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Group III: Propofol 4 microg/ml and Rimifentanil 4 ng/ml with fluid expansion of Hetastarch 10 ml/kg
Number of subjects: 90
Study: 15007373

Group type: EXPERIMENTAL
Intervention: Transdermal nicotine (TN)
Number of subjects: 320

Group type: COMPARATOR
Intervention: Nicotine nasal spray (NS)
Number of subjects: 320
Study: 11727192

Group type: EXPERIMENTAL
Intervention: Long-acting cephalosporine (ceftriaxone) with metronidazole
Number of subjects: 2481

Group type: COMPARATOR
Intervention: Long-acting cephalosporine (ceftriaxone) without metronidazole
Number of subjects: 2481

Group type: EXPERIMENTAL
Intervention: Short-acting cephalosporines with metronidazole
Number of subjects: 2481

Group type: COMPARATOR
Intervention: Short-acting cephalosporines without metronidazole
Number of subjects: 2481

Group type: EXPERIMENTAL
Intervention: Broad-spectrum penicillines with metronidazole
Number of subjects: 2481

Group type: COMPARATOR
Intervention: Broad-spectrum penicillines without metronidazole
Number of subjects: 2481
Study: 9517954

Group type: EXPERIMENTAL
Intervention: terbinafine
Number of subjects: 12

Group type: COMPARATOR
Intervention: control (no terbinafine)
Number of subjects: 12
Study: 7788917

Group type: EXPERIMENTAL
Intervention: Head-up tilt testing at 60 degrees
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Head-up tilt testing at 70 degrees
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Head-up tilt testing at 80 degrees
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Low-dose isoproterenol infusion during tilt testing at 60 degrees
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Low-dose isoproterenol infusion during tilt testing at 70 degrees
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Low-dose isoproterenol infusion during tilt testing at 80 degrees
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Tilt testing at 70 degrees with 1.5 micrograms/min isoproterenol infusion
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Tilt testing at 70 degrees with 3 micrograms/min isoproterenol infusion
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Tilt testing at 70 degrees with 5 micrograms/min isoproterenol infusion
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Tilt testing during 3 micrograms/min isoproterenol infusion
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Tilt testing during 5 micrograms/min isoproterenol infusion
Number of subjects: 150
Study: 2531611

Group type: EXPERIMENTAL
Intervention: MPA alone
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: MPA plus psychotherapy
Number of subjects: 84

Group type: COMPARATOR
Intervention: Placebo alone
Number of subjects: 84

Group type: COMPARATOR
Intervention: Placebo plus psychotherapy
Number of subjects: 84
Study: 1098155

Group type: EXPERIMENTAL
Intervention: 100 mg mebendazole twice a day for three days
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: 100 mg mebendazole twice a day for four days
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study: 31909861

Group type: EXPERIMENTAL
Intervention: Bioresorbable scaffold (BRS) derived PSP score
Number of subjects: 2348

Group type: EXPERIMENTAL
Intervention: Optimal sizing
Number of subjects: 2348

Group type: EXPERIMENTAL
Intervention: Optimal predilation
Number of subjects: 2348

Group type: EXPERIMENTAL
Intervention: New PSP scoring system
Number of subjects: 2348
Study: 30646948

Group type: EXPERIMENTAL
Intervention: Nurse-led, telephone-based follow-up
Number of subjects: 771

Group type: COMPARATOR
Intervention: Control (routine follow-up)
Number of subjects: 771
Study: 28246206

Group type: EXPERIMENTAL
Intervention: gemcitabine/simtuzumab 700 mg
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: gemcitabine/simtuzumab 200 mg
Number of subjects: 240

Group type: COMPARATOR
Intervention: gemcitabine/placebo
Number of subjects: 240
Study: 26939315

Group type: EXPERIMENTAL
Intervention: Acupuncture (Tianshu, Zusanli, Shangjuxu, Taichong, Sanyinjiao, Yintang, Baihui), once a day, 5 treatments a week for 4 weeks.
Number of subjects: 60

Group type: COMPARATOR
Intervention: Lactulose oral solution, 15 mL three times a day for 4 weeks.
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Acupuncture (same as above)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Lactulose oral solution (same as above)
Number of subjects: 60
Study: 23936893

Group type: EXPERIMENTAL
Intervention: Research assistant‐directed distraction
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Parent‐directed distraction
Number of subjects: 99

Group type: COMPARATOR
Intervention: Typical care
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Distressed preneedle toddlers (regardless of treatment group)
Number of subjects: 99
Study: 21592873

Group type: EXPERIMENTAL
Intervention: 22-gauge needle
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: 25-gauge needle
Number of subjects: 50

Group type: COMPARATOR
Intervention: Both 22-gauge and 25-gauge needles
Number of subjects: 50
Study: 18430242

Group type: EXPERIMENTAL
Intervention: Subgrouping using a novel tool combined with targeted treatment delivered by trained physiotherapists
Number of subjects: 800

Group type: COMPARATOR
Intervention: Best current care
Number of subjects: 800
Study: 16942963

Group type: EXPERIMENTAL
Intervention: Virtual Reality Exposure (VRE)
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Standard Exposure (SE)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Wait List (WL)
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Virtual Reality Exposure (VRE) and Standard Exposure (SE)
Number of subjects: 83